ENXTPA:TNG

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. More Details


Snowflake Analysis

Excellent balance sheet with high growth potential.

Share Price & News

How has Transgene's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TNG is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: TNG's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

5.2%

TNG

3.0%

FR Biotechs

1.1%

FR Market


1 Year Return

-13.8%

TNG

35.5%

FR Biotechs

-2.6%

FR Market

Return vs Industry: TNG underperformed the French Biotechs industry which returned 27.7% over the past year.

Return vs Market: TNG underperformed the French Market which returned -3% over the past year.


Shareholder returns

TNGIndustryMarket
7 Day5.2%3.0%1.1%
30 Day18.0%12.0%15.2%
90 Day15.3%22.3%11.6%
1 Year-13.8%-13.8%35.5%35.5%-0.6%-2.6%
3 Year-38.7%-40.2%-31.8%-31.9%16.8%7.1%
5 Year-32.5%-35.6%-63.5%-63.7%48.9%28.7%

Long-Term Price Volatility Vs. Market

How volatile is Transgene's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Transgene undervalued compared to its fair value and its price relative to the market?

2.17x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TNG's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TNG's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TNG is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: TNG is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TNG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TNG is good value based on its PB Ratio (2.2x) compared to the FR Biotechs industry average (3x).


Next Steps

Future Growth

How is Transgene forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

29.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TNG is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.6%).

Earnings vs Market: TNG is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: TNG's is expected to become profitable in the next 3 years.

Revenue vs Market: TNG's revenue (34.5% per year) is forecast to grow faster than the French market (7.3% per year).

High Growth Revenue: TNG's revenue (34.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TNG's Return on Equity is forecast to be low in 3 years time (0.6%).


Next Steps

Past Performance

How has Transgene performed over the past 5 years?

33.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TNG is currently unprofitable.

Growing Profit Margin: TNG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TNG is unprofitable, but has reduced losses over the past 5 years at a rate of 33.9% per year.

Accelerating Growth: Unable to compare TNG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TNG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11.2%).


Return on Equity

High ROE: TNG has a negative Return on Equity (-8.83%), as it is currently unprofitable.


Next Steps

Financial Health

How is Transgene's financial position?


Financial Position Analysis

Short Term Liabilities: TNG's short term assets (€57.4M) exceed its short term liabilities (€23.6M).

Long Term Liabilities: TNG's short term assets (€57.4M) exceed its long term liabilities (€21.9M).


Debt to Equity History and Analysis

Debt Level: TNG's debt to equity ratio (36%) is considered satisfactory.

Reducing Debt: TNG's debt to equity ratio has reduced from 115% to 36% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TNG has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: TNG has less than a year of cash runway if free cash flow continues to grow at historical rates of 14% each year.


Next Steps

Dividend

What is Transgene current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TNG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TNG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TNG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TNG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TNG's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.8yrs

Average management tenure


CEO

Philippe Archinard (61 yo)

15.92yrs

Tenure

€1,411,000

Compensation

Dr. Philippe Archinard, Ph.D., has been the Chairman of Transgene SA since June 17, 2010 and its Chief Executive Officer since December 6, 2004. Dr. Archinard serves as a Scientific Director of Mérieux All...


CEO Compensation Analysis

Compensation vs Market: Philippe's total compensation ($USD1.68M) is above average for companies of similar size in the French market ($USD479.20K).

Compensation vs Earnings: Philippe's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Philippe Archinard
Chairman & CEO15.92yrs€1.41m0.14%
€ 193.4k
Christophe Ancel
Deputy CEO & VP of Quality6.83yrs€317.00kno data
Jean-Philippe Del
CFO & VP of Finance6.83yrsno datano data
Elisabetta Castelli
Director of Investor Relations12.83yrsno datano data
John Felitti
VP, General Counsel & Corporate Secretary4.67yrsno datano data
Lucie Larguier
Director of Corporate Communications & IRno datano datano data
Thibaut Fayet
Vice President of Strategic Allianceno datano datano data
Philippe Slos
Head of Preclinical Regulatory Laboratory15.58yrsno datano data
Éric Quéméneur
Executive VP and VP of Research & Development6.17yrsno datano data
Maud Brandely-Talbot
Chief Medical Officer4.67yrsno datano data
Guy Crespy
Executive Officerno datano datano data
Nicolas Ver Hulst
Executive Officerno datano datano data

6.8yrs

Average Tenure

55yo

Average Age

Experienced Management: TNG's management team is seasoned and experienced (6.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Philippe Archinard
Chairman & CEO15.92yrs€1.41m0.14%
€ 193.4k
Benoit Habert
Independent Director20.83yrs€37.00k0.089%
€ 123.7k
Alain Merieux
Honorary Chairman0.83yrno data60.14%
€ 83.6m
Dominique Takizawa
Director18.83yrsno datano data
Pierre Chambon
Member of Scientific Advisory Boardno datano datano data
Christopher Walker
Member of Scientific Advisory Boardno datano datano data
Jean-Claude Weill
Member of Scientific Advisory Boardno datano datano data
Rafick-Pierre Sekaly
Member of Scientific Advisory Boardno datano datano data
James Santo
Member of Scientific Advisory Boardno datano datano data
Pierre Coulie
Member of Scientific Advisory Boardno datano datano data
Jean-Yves Blay
Member of Scientific Advisory Boardno datano datano data
Marie-Yvonne Landel-Meunier
Independent Director3.42yrs€51.00kno data

10.4yrs

Average Tenure

62yo

Average Age

Experienced Board: TNG's board of directors are seasoned and experienced ( 10.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Transgene SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Transgene SA
  • Ticker: TNG
  • Exchange: ENXTPA
  • Founded: 1979
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €139.071m
  • Shares outstanding: 83.68m
  • Website: https://www.transgene.fr

Number of Employees


Location

  • Transgene SA
  • 400 Boulevard Gonthier d’Andernach
  • Parc d’Innovation – CS80166
  • Illkirch-Graffenstaden
  • Alsace
  • 67405
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TGNADB (Deutsche Boerse AG)YesOrdinary SharesDEEURMar 1998
TNGENXTPA (Euronext Paris)YesOrdinary SharesFREURMar 1998
TRGN.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMar 1998
0OCQLSE (London Stock Exchange)YesOrdinary SharesGBEURMar 1998
TNGPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURMar 1998

Biography

Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company’s lead clinical-stage prog...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/26 19:59
End of Day Share Price2020/11/26 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.